Early administration of non-vitamin K antagonist oral anticoagulants for acute ischemic stroke patients with atrial fibrillation in comparison with warfarin mostly combined with heparin

Circulation Journal

Volumn 79, Issue 4, 2015, Pages 862-866

  Nomura, Eiichi ^a,b   Ohshita, Tomohiko ^b   Imamura, Eiji ^b   Wakabayashi, Shinichi ^b   Kajikawa, Hiroshi ^b   Hosomi, Naohisa ^c   Matsumoto, Masayasu ^c  

^a HIROSHIMA CITY HOSPITAL   (Japan)

^b Suiseikai Kajikawa Hospital   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Acute ischemic stroke; Atrial fibrillation; Diffusion weighted image; Non vitamin K antagonist oral anticoagulants; Warfarin

Indexed keywords

ANTIVITAMIN K; DABIGATRAN; HEPARIN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; VITAMIN K GROUP;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; CREATININE CLEARANCE; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PROTHROMBIN TIME; VERY ELDERLY; ACUTE DISEASE; ATRIAL FIBRILLATION; COMPARATIVE STUDY; COMPLICATION; ORAL DRUG ADMINISTRATION; RADIOGRAPHY; STROKE; TIME;

ACUTE DISEASE; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; HEPARIN; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; STROKE; TIME FACTORS; VITAMIN K; WARFARIN;

EID: 84925651405     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-14-0793     Document Type: Article

References (25)

1. Arboix A, Alió J. Acute cardioembolic cerebral infarction: Answers to clinical questions. Curr Cardiol Rev 2012; 8: 54–67.
2. Arboix A, Alió J. Acute cardioembolic stroke: An update. Expert Rev Cardiovasc Ther 2011; 9: 367–379.
3. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255–1262.
4. Pisters R, Lane DA, Marin F, Camm AJ, Lip GY. Stroke and thromboembolism in atrial fibrillation. Circ J 2012; 76: 2289–2304.
5. Guedes LC, Ferro JM. A systematic review of immediate anticoagulation for ischemic stroke of presumed cardioembolic origin. Stroke 2008; 39: e81–e82, doi:10.1161/STROKEAHA.107.513200.
6. Micheli S, Agnelli G, Caso V, Paciaroni M. Clinical benefit of early anticoagulation in cardioembolic stroke. Cerebrovasc Dis 2008; 25: 289–296.
7. Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: A meta-analysis of randomized controlled trials. Stroke 2007; 38: 423–430.
8. Kang DW, Lattimore SU, Latour LL, Warach S. Silent ischemic lesion recurrence on magnetic resonance imaging predicts subsequent clinical vascular events. Arch Neurol 2006; 63: 1730–1733.
9. Kim WJ, Kim JH, Ko Y, Park JH, Yang MH, Jang MS, et al. Can early ischemic lesion recurrence on diffusion-weighted MRI affect functional outcome after acute ischemic stroke? J Clin Neurol 2010; 6: 19–26.
10. Nolte CH, Albach FN, Heuschmann PU, Brunecker P, Villringer K, Endres M, et al. Silent new DWI lesions within the first week afterstroke. Cerebrovasc Dis 2012; 33: 248–254.
11. Nomura E, Ohshita T, Imamura E, Wakabayashi S, Kajikawa H, Matsumoto M. Can early effective anticoagulation prevent new lesions on magnetic resonance imaging in acute cardioembolic stroke? J Stroke Cerebrovasc Dis 2014; 23: 2099–2104.
12. Gómez-Outes A, Terleira-Fernández AI, Calvo-Rojas G, Suárez-Gea ML, Vargas-Castrillón E. Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: A systematic review and meta-analysis of subgroups. Thrombosis 2013; 2013: 640723, doi:10.1155/2013/640723.
13. Ntaios G, Papavasileiou V, Diener HC, Makaritsis K, Michel P. Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: A systematic review and meta-analysis of randomized controlled trials. Stroke 2012; 43: 3298–3304.
14. Komori M, Yasaka M, Kokuba K, Matsuoka H, Fujimoto S, Yoshida M, et al. Intracranial hemorrhage during dabigatran treatment. Circ J 2014; 78: 1335–1341.
15. Shibazaki K, Kimura K, Aoki J, Saji N, Sakai K. Early initiation of new oral anticoagulants in acute stroke and TIA patients with nonvalvular atrial fibrillation. J Neurol Sci 2013; 331: 90–93.
16. D’Angelo A, Della Valle P, Crippa L, Fattorini A, Pattarini E, Viganò D’Angelo S. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment. Haematologica 2002; 87: 1074–1080.
17. Azoulay L, Dell’Aniello S, Simon TA, Renoux C, Suissa S. Initiation of warfarin in patients with atrial fibrillation: Early effects on ischaemic strokes. Eur Heart J 2014; 35: 1881–1887.
18. Yasaka M, Minematsu K, Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med 2001; 40: 1183–1188.
19. Maccallum PK, Mathur R, Hull SA, Saja K, Green L, Morris JK, et al. Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation: A cross-sectional study. BMJ Open 2013; 3: e003343, doi:10.1136/bmjopen-2013-003343.
20. Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low molecularweight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: A double-blind randomised study: HAEST Study Group: Heparin in Acute Embolic Stroke Trial. Lancet 2000; 355: 1205–1210.
21. Saxena R, Lewis S, Berge E, Sandercock PA, Koudstaal PJ. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial. Stroke 2001; 32: 2333–2337.
22. Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, et al. Rivaroxaban vs. warfarin in Japanese patients with nonvalvular atrial fibrillation in relation to age. Circ J 2014; 78: 1349–1356.
23. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, et al. American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology: Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44: 870–947.
24. Hallevi H, Albright KC, Martin-Schild S, Barreto AD, Savitz SI, Escobar MA, et al. Anticoagulation after cardioembolic stroke: To bridge or not to bridge? Arch Neurol 2008; 65: 1169–1173.
25. Diener HC: “The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation.” Thromb Haemost 2013; 110: 493–495.